Graham S Scott, Grundy Quinn, Sharma Nandini, Edward Jade Shiva, Barbour Joshua B, Rousseau Justin F, Majdik Zoltan P, Bero Lisa
Department of Rhetoric & Writing, The University of Texas at Austin, Austin, TX, USA.
Laurence Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada.
Res Integr Peer Rev. 2025 May 14;10(1):6. doi: 10.1186/s41073-025-00164-0.
Industry funding and author conflicts of interest (COI) have been consistently shown to introduce bias into agenda-setting and results-reporting in biomedical research. Accordingly, maintaining public trust, diminishing patient harm, and securing the integrity of the biomedical research enterprise are critical policy priorities. In this context, a coordinated and methodical research effort is required to effectively identify which policy interventions are most likely to mitigate against the risks of funding bias. Subsequently this scoping review aims to identify and synthesize the available research on policy mechanisms designed to address funding bias and COI in biomedical research.
We searched PubMed for peer-reviewed, empirical analyses of policy mechanisms designed to address industry sponsorship of research studies, author industry affiliation, and author COI at any stage of the biomedical research process and published between January 2009 and 28 August 2023. The review identified literature conducting five primary analysis types: (1) surveys of COI policies, (2) disclosure compliance analyses, (3) disclosure concordance analyses, (4) COI policy effects analyses, and (5) studies of policy perceptions and contexts. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies.
Six thousand three hundreds eighty five articles were screened, and 81 studies were included. Studies were conducted in 11 geographic regions, with studies of international scope being the most common. Most available research is devoted to evaluating the prevalence, nature, and effects of author COI disclosure policies. This evidence demonstrates that while disclosure policies are pervasive, those policies are not consistently designed, implemented, or enforced. The available evidence also indicates that COI disclosure policies are not particularly effective in mitigating risk of bias or subsequent negative externalities.
The results of this review indicate that the COI policy landscape could benefit from a significant shift in the research agenda. The available literature predominantly focuses on a single policy intervention-author disclosure requirements. As a result, new lines of research are needed to establish a more robust evidence-based policy landscape. There is a particular need for implementation research, greater attention to the structural conditions that create COI, and evaluation of policy mechanisms other than disclosure.
一直以来,行业资助和作者利益冲突被证明会给生物医学研究的议程设定和结果报告带来偏差。因此,维护公众信任、减少患者伤害以及确保生物医学研究事业的诚信是关键的政策优先事项。在此背景下,需要开展协调一致且有条不紊的研究工作,以有效确定哪些政策干预措施最有可能降低资助偏差风险。随后,本范围综述旨在识别和综合关于旨在解决生物医学研究中资助偏差和利益冲突的政策机制的现有研究。
我们在PubMed上搜索了2009年至[具体年份]8月28日期间发表的、对旨在解决生物医学研究过程中任何阶段的研究行业资助、作者行业从属关系和作者利益冲突的政策机制进行同行评审的实证分析。该综述确定了进行五种主要分析类型的文献:(1)利益冲突政策调查,(2)披露合规性分析,(3)披露一致性分析,(4)利益冲突政策效果分析,以及(5)政策认知和背景研究。大多数现有研究致力于评估作者利益冲突披露政策的普遍性、性质和效果。
筛选了6385篇文章,纳入了81项研究。研究在11个地理区域开展,其中国际范围的研究最为常见。大多数现有研究致力于评估作者利益冲突披露政策的普遍性、性质和效果。这一证据表明,虽然披露政策普遍存在,但这些政策的设计、实施或执行并不一致。现有证据还表明,利益冲突披露政策在减轻偏差风险或后续负面外部性方面并非特别有效。
本综述结果表明,利益冲突政策格局可能会从研究议程的重大转变中受益。现有文献主要关注单一政策干预措施——作者披露要求。因此,需要新的研究方向来建立更强大的循证政策格局。尤其需要开展实施研究,更加关注产生利益冲突的结构条件,并评估除披露之外的政策机制。 (注:原文中2023年8月28日中的年份部分缺失,翻译时保留原文格式)